Literature DB >> 17066421

Expression and prognostic significance of angiopoietin in colorectal carcinoma.

Yuan-Chang Chung1, Yung-Chi Hou, Ching-Nien Chang, Tzong-Hsiung Hseu.   

Abstract

BACKGROUND AND OBJECTIVES: Growth and metastasis of malignant tumors depend on the angiogenesis. The aim of this study was to elucidate the prognostic significance of angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) expression in advanced colorectal carcinoma.
METHODS: Totally, 101 patients with surgically resected advanced colorectal carcinomas were enrolled. The tumor expressions of Ang-1 and Ang-2 were evaluated immunohistochemically, and their relationships with clinicopathological factors and prognosis were investigated. Tumor microvessel density (MVD) was also calculated and correlated with angiopoietin expression.
RESULTS: Ang-1 and Ang-2 were detected in 26 (25.7%) and 45 (44.6%), respectively, of 101 cancerous lesions. Overexpression of Ang-1 was correlated with high MVD. Overexpression of Ang-2 was correlated with lymph node metastasis, venous invasion, preoperative carcinoembryonic antigen levels, and high MVD (P < or = 0.05). MVD was not significantly upregulated by Ang-1 expression, but was significantly upregulated by Ang-2 expression (P < or = 0.01). However, only patients with Ang-2 overexpression showed a significantly worse prognosis than those without Ang-2 overexpression. Multivariate analysis with logistic regression for 5-year survival revealed that cancerous stage and Ang-2 overexpression were independent prognostic indicators.
CONCLUSIONS: The Ang-1 expression correlated with MVD. However, Ang-2 expression was a useful prognostic marker in the management of patients with advanced colorectal carcinoma. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17066421     DOI: 10.1002/jso.20423

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

Review 1.  Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer.

Authors:  A D Karatzanis; E Koudounarakis; I Papadakis; G Velegrakis
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-21       Impact factor: 2.503

Review 2.  Meeting the biologic challenge of colorectal metastases.

Authors:  Harold J Wanebo; Mark LeGolvan; Philip B Paty; Sukamal Saha; Markus Zuber; Michael I D'Angelica; Nancey E Kemeny
Journal:  Clin Exp Metastasis       Date:  2012-10-10       Impact factor: 5.150

3.  The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).

Authors:  Johanna C Bendell; Tamara Sauri; Antonio Cubillo Gracián; Rafael Alvarez; Carlos López-López; Pilar García-Alfonso; Maen Hussein; Maria-Luisa Limon Miron; Andrés Cervantes; Clara Montagut; Cristina Santos Vivas; Alberto Bessudo; Patricia Plezia; Veerle Moons; Johannes Andel; Jaafar Bennouna; Andre van der Westhuizen; Leslie Samuel; Simona Rossomanno; Christophe Boetsch; Angelika Lahr; Izolda Franjkovic; Florian Heil; Katharina Lechner; Oliver Krieter; Herbert Hurwitz
Journal:  Oncologist       Date:  2019-09-30

Review 4.  Fetuin-A and angiopoietins in obesity and type 2 diabetes mellitus.

Authors:  Sazan Rasul; Ludwig Wagner; Alexandra Kautzky-Willer
Journal:  Endocrine       Date:  2012-07-21       Impact factor: 3.633

Review 5.  Targeting the ANGPT-TIE2 pathway in malignancy.

Authors:  Hanhua Huang; Abhijit Bhat; Gary Woodnutt; Rodney Lappe
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

6.  Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

Authors:  V Goede; O Coutelle; J Neuneier; A Reinacher-Schick; R Schnell; T C Koslowsky; M R Weihrauch; B Cremer; H Kashkar; M Odenthal; H G Augustin; W Schmiegel; M Hallek; U T Hacker
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

7.  Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer.

Authors:  E Volkova; J A Willis; J E Wells; B A Robinson; G U Dachs; M J Currie
Journal:  Br J Cancer       Date:  2010-11-16       Impact factor: 7.640

8.  Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2.

Authors:  Sigve Andersen; Tom Donnem; Khalid Al-Shibli; Samer Al-Saad; Helge Stenvold; Lill-Tove Busund; Roy M Bremnes
Journal:  PLoS One       Date:  2011-05-16       Impact factor: 3.240

9.  High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes.

Authors:  C-L Cheng; H-A Hou; J-Y Jhuang; C-W Lin; C-Y Chen; J-L Tang; W-C Chou; M-H Tseng; M Yao; S-Y Huang; B-S Ko; S-C Hsu; S-J Wu; W Tsay; Y-C Chen; H-F Tien
Journal:  Br J Cancer       Date:  2011-08-30       Impact factor: 7.640

10.  A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.

Authors:  M Peeters; A H Strickland; M Lichinitser; A V S Suresh; G Manikhas; J Shapiro; W Rogowski; X Huang; B Wu; D Warner; R Jain; N C Tebbutt
Journal:  Br J Cancer       Date:  2013-01-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.